명상도서관

명상도서관

A Large Randomized Trial: Effects of Mindfulness-Based Stress Reduction (MBSR) for Breast Cancer (BC) Survivors on Salivary Cortisol and IL-6 자세히보기
  • 자료유형학술지논문
  • 저자명Lengacher, Cecile A.,Reich, Richard R.,Paterson, Carly L.,Shelton, Melissa,Shivers, Steve,Ramesar, Sophia,Pleasant, Michelle L.,Budhrani-Shani, Pinky,Groer, Maureen,Post-White, Janice
  • 학회/출판사/기관명SAGE SCIENCE PRESS
  • 출판년도2019
  • 언어영어
  • 학술지명/학위논문주기BIOLOGICAL RESEARCH FOR NURSING
  • 발행사항Vol.21No.1[2019]_x000D_
  • ISBN/ISSN1099-8004
  • 소개/요약Breast cancer survivors (BCS) often experience psychological and physiological symptoms after cancer treatment. Mindfulness-based stress reduction (MBSR), a complementary and alternative therapy, has reduced subjective measures of stress, anxiety, and fatigue among BCS. Little is known, however, about how MBSR affects objective markers of stress, specifically the stress hormone cortisol and the pro-inflammatory cytokine interleukin-6 (IL-6). In the present study, BCS (N ¼ 322) were randomly assigned to a 6-week MBSR program for BC or usual-care control. Measurements of cortisol, IL-6, symptoms, and quality of life were obtained at orientation and 6 weeks. Cortisol and IL-6 were also measured prior to and after the MBSR(BC) class Weeks 1 and 6. The mean age of participants was 56.6 years and 69.4% were White non-Hispanic. Most had Stage I (33.8%) or II (35.7%) BC, and 35.7% had received chemotherapy and radiation. Cortisol levels were reduced immediately following MBSR(BC) class compared to before the class Weeks 1 and 6 (Wilcoxon-signed rank test; p < .01, d ¼ .52-.56). IL-6 was significantly reduced from pre-to postclass at Week 6 (Wilcoxon-signed rank test; p < .01, d ¼ .21). No differences were observed between the MBSR(BC) and control groups from baseline to Week 6 using linear mixed models. Significant relationships with small effect sizes were observed between IL-6 and both symptoms and quality of life in both groups. Results support the use of MBSR(BC) to reduce salivary cortisol and IL-6 levels in the short term in BCS.